10.69
+0.175(+1.67%)
Currency In USD
| Previous Close | 10.51 |
| Open | 10.02 |
| Day High | 10.92 |
| Day Low | 9.89 |
| 52-Week High | 14.51 |
| 52-Week Low | 5.9 |
| Volume | 853,367.47 |
| Average Volume | 855,616 |
| Market Cap | 683.42M |
| PE | -9.37 |
| EPS | -1.14 |
| Moving Average 50 Days | 11.53 |
| Moving Average 200 Days | 10.45 |
| Change | 0.18 |
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
GlobeNewswire Inc.
Mar 11, 2026 11:00 AM GMT
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clini
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
GlobeNewswire Inc.
Feb 12, 2026 12:00 PM GMT
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: